BobF, don't forget about R435, which is a variant of R327 aimed specifically at oral administration.
Source: https://finance.yahoo.com/news/recce-pharmaceuticals-announces-positive-oral-120000992.html
So, over four years ago, they split off oral dosage into a different development path, so that it will not interrupt development of the flagship product R327, which is aimed at IV administration targeting sepsis in the blood. That is it's primary goal.
They also created R529, for the same purpose; to not hold up development of R327, yet allow for specifically targeting viral infections.
Both variants as far as I understand, take a much lower priority to R327 and quite rightly so.
- Forums
- ASX - By Stock
- [INTERVIEW] Recce gearing up for Indonesian trials
RCE
recce pharmaceuticals ltd
Add to My Watchlist
6.56%
!
32.5¢

BobF, don't forget about R435, which is a variant of R327 aimed...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
32.5¢ |
Change
0.020(6.56%) |
Mkt cap ! $93.72M |
Open | High | Low | Value | Volume |
30.5¢ | 33.0¢ | 30.0¢ | $75.15K | 239.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10934 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.5¢ | 14999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10934 | 0.310 |
1 | 47005 | 0.305 |
5 | 26941 | 0.300 |
1 | 5000 | 0.295 |
8 | 49533 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 14999 | 1 |
0.330 | 6693 | 1 |
0.350 | 30000 | 2 |
0.375 | 8002 | 1 |
0.380 | 6820 | 2 |
Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
RC1
REDCASTLE RESOURCES LIMITED
Ronald Miller, Non-Executive Director
Ronald Miller
Non-Executive Director
SPONSORED BY The Market Online